BioNTech (BNTX) stock was under pressure on May 5 after the multinational announced plans to eliminate up to 1,860 roles as it continues to grapple with declining COVID-19 vaccine sales. The selloff saw BNTX slip below its 50-day moving average (MA) on Tuesday, signaling downward momentum could sustain in the near term. More News from Barchart Including this pullback, BioNTech stock is down roughly 20% versus its year-to-date high. www.barchart.com What Layoffs Really Mean for BioNTech Stock The l ...